Biohaven [BHVN] vs Capricor [CAPR] Detailed Stock Comparison

Biohaven Ltd.

NYSE
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 16 vital metrics comparison: Biohaven Ltd. wins in 1 metrics, Capricor Therapeutics Inc. wins in 11 metrics, with 2 ties. Capricor Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biohaven Ltd. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) N/A -15.61 N/A
Price-to-Book Ratio 26.84 6.62 Capricor Therapeutics Inc.
Debt-to-Equity Ratio 546.58 4.75 Capricor Therapeutics Inc.
PEG Ratio -5.26 -0.05 Capricor Therapeutics Inc.
EV/EBITDA -2.22 -16.23 Biohaven Ltd.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) 0.00% 0.00% Tie
Return on Equity -310.75% -46.56% Capricor Therapeutics Inc.
Return on Assets (TTM) -83.02% -25.68% Capricor Therapeutics Inc.
Free Cash Flow (TTM) $-610.15M $-81.54M Capricor Therapeutics Inc.
1-Year Return -27.04% 119.02% Capricor Therapeutics Inc.
Enterprise Value $1.55B $1.72B Capricor Therapeutics Inc.
Revenue per Share (TTM) N/A $0 N/A
Earnings per Share (Diluted) $-6.86 $-2.26 Capricor Therapeutics Inc.
Beta (Stock Volatility) 3.62 0.48 Capricor Therapeutics Inc.
Short % of Float 20.25% 19.17% Capricor Therapeutics Inc.

Biohaven Ltd. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

BHVN
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biohaven Ltd.7.62%9.17%38.58%25.93%7.62%11.99%
Capricor Therapeutics Inc.3.57%2.14%-7.19%-12.57%0.64%-5.62%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biohaven Ltd.-27.04%-52.30%54.52%-37.02%-37.02%-37.02%
Capricor Therapeutics Inc.119.02%445.45%385.88%-42.15%-92.18%-98.04%

Performance & Financial Health Analysis: Biohaven Ltd. vs Capricor Therapeutics Inc.

MetricBHVNCAPR
Market Information
Market Cap i$1.49B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i1,841,635987,380
90 Day Avg. Volume i2,141,9921,234,213
Last Close$12.14$26.72
52 Week Range$7.48 - $18.57$4.30 - $40.37
% from 52W High-34.61%-33.81%
All-Time High$67.86 (Jun 03, 2019)$3,500.00 (Oct 22, 2007)
% from All-Time High-82.11%-99.24%
Growth Metrics
Quarterly Revenue GrowthN/AN/A
Quarterly Earnings GrowthN/A-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i0.00%0.00%
Return on Equity (TTM) i-3.11%-0.47%
Debt to Equity (MRQ) i546.584.75
Cash & Liquidity
Book Value per Share (MRQ)$0.39$5.33
Cash per Share (MRQ)$2.12$5.53
Operating Cash Flow (TTM) i$-609,438,016$-69,811,264
Levered Free Cash Flow (TTM) i$-358,118,432$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Biohaven Ltd. vs Capricor Therapeutics Inc.

MetricBHVN (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-15.61
Forward P/E i-5.26-56.73
PEG Ratio i-5.26-0.05
Price to Sales (TTM) iN/AN/A
Price to Book (MRQ) i26.846.62
Market Capitalization
Market Capitalization i$1.49B$2.04B
Enterprise Value i$1.55B$1.72B
Enterprise Value Metrics
Enterprise to Revenue iN/AN/A
Enterprise to EBITDA i-2.22-16.23
Risk & Other Metrics
Beta i3.620.48
Book Value per Share (MRQ) i$0.39$5.33

Financial Statements Comparison: Biohaven Ltd. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBHVN (2025)CAPR (2025)
Revenue/Sales i00
Cost of Goods Sold iN/AN/A
COGS % of Revenue i--
Gross Profit iN/AN/A
Gross Margin i--
Research & Development i635.07M84.45M
Operating Income (EBIT) i-745.38M-108.14M
Operating Margin i--
EBITDA i-735.46M-106.21M
EBITDA Margin i--
Pre-Tax Income i-737.38M-105.04M
Pre-Tax Income % of Revenue i--
Income Tax i1.44M1,600
Income Tax % of Revenue i--
Net Income (Profit) i-738.82M-105.04M
Profit Margin i--

Balance Sheet & Liquidity Metrics

MetricBHVN (2025)CAPR (2025)
Cash & Equivalents i229.96M287.85M
Total Current Assets i368.33M322.94M
Total Current Assets % of Revenue i--
Total Current Liabilities i115.93M35.84M
Total Current Liabilities % of Revenue i--
Long-Term Debt i278.86M14.32M
Long-Term Debt % of Revenue i--
Total Shareholders Equity i52.07M305.79M
Retained Earnings i-2.08B-304.88M
Retained Earnings % of Revenue i--
Property, Plant & Equipment i45.06M22.27M

Cash Flow Statement Comparison

MetricBHVN (2025)CAPR (2025)
Operating Cash Flow i-617.91M-71.86M
Operating Cash Flow % of Revenue i--
Capital Expenditures i-715,000-11.72M
Free Cash Flow i-610.15M-81.54M
FCF Margin i--
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBHVNCAPR
Shares Short i23.77M10.04M
Short Ratio i9.217.73
Short % of Float i20.25%19.17%
Shares Outstanding i132.78M57.37M
Float Shares i123.86M48.61M
% Held by Insiders i11.09%9.47%
% Held by Institutions i91.64%53.91%
% Held by Public i-2.73%36.62%

Dividend Analysis & Yield Comparison: Biohaven Ltd. vs Capricor Therapeutics Inc.

MetricBHVNCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A